// App-Quantinova.ai

TPS632 : A Phase 1 study to evaluate the safety, pharmacokinetics, immunogenicity, and antitumor activity of MEDI4276 in patients with select HER2-expressing advanced solid tumors.

Researchers

Presenter

  • Erika Paige Hamilton

Principal Investigators

  • Manish R. Patel

  • Mark D. Pegram

  • Antoinette R. Tan

  • Anna Maria Storniolo

  • John Li

  • Xiang-Qing Yu

  • Anita Scheuber

Medical Centers

  • Sarah Cannon Research Institute/Tennessee Oncology, Brentwood, TN

  • Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL

  • Stanford School of Medicine, Stanford, CA

  • Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC

  • Melvin and Bren Simon Cancer Center at Indiana University, Indianapolis, IN

  • MedImmune, Gaithersburg, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Solid malignancies

  • Gastric Cancer

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Open Label

  • Expansion Study

  • Dose Escalation

  • First-In-Human

Phase

  • I

Study Id's

  • NCT02576548

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved